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Following myocardial infarction, wound healing takes place in the infarct area where the non-viable cardiac tissue is
replaced by a scar. Inadequate wound healing or insufficient maintenance of the extracellular matrix in the scar can
lead to excessive dilatation of the ventricles, one of the hallmarks of congestive heart failure. Therefore, it is
important to better understand the wound-healing process in the heart and to develop new therapeutic agents
that target the infarct area in order to maintain an adequate cardiac function. One of these potential novel
therapeutic targets is Wnt signaling. Wnt signaling plays an important role in embryonic myocardial development
but in the adult heart the pathway is thought to be silent. However, there is increasing evidence that components
of the Wnt pathway are re-expressed during cardiac repair, implying a regulatory role. Recently, several studies have
been published where the effect of interventions in Wnt signaling on infarct healing has been studied. In this
review, we will summarize the results of these studies and discuss the effects of these interventions on the different
cell types that are involved in the wound healing process.
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Introduction
Cardiovascular diseases (CVDs) are the leading causes of
mortality worldwide. More people die from CVDs than
from any other disease. According to WHO, 17.3 million
people died from CVDs in 2008, representing 30% of all
global deaths. Of these deaths, 7.3 million were due to
coronary heart disease [1].
Myocardial infarction (MI) is the result of an occlusion
of a coronary artery, caused by a thrombus or an ather-
omatous ruptured plaque, which deprives the myocar-
dium from sufficient blood flow. This leads to ischemia
and eventually death of cardiomyocytes [2]. The location
and duration of the occlusion is determinant for the out-
come. However, during the last decades, more patients
enter the wound-healing phase due to improvements in
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Wound healing is a complex process of consecutive cas-
cades involving several cell types, and finalizes with scar
formation. The first phase begins when necrotic cardio-
myocytes trigger an inflammatory response by activation
of the complement cascade [3]. In humans, the primary
inflammatory phase occurs within 12 to 16 hours after MI
and mainly attracts polymorphonuclear leukocytes
(PMNLs) into the infarcted area. Peak numbers of PMNLs
are observed at 24 to 48 hours after infarction. These cells
partly remove the cellular debris by phagocytosis and at-
tract lymphocytes, which in turn causes infiltration of
macrophages that help to remove the dead cardiomyo-
cytes [2,4]. The infiltrated inflammatory cells not only
clear dead cells by phagocytosis but also release proteo-
lytic enzymes and reactive oxygen species, which lead to
additional cardiomyocyte death [5]. The second phase is
defined by deposition of granulation tissue and starts two
to three days after infarction. Here, new extracellular
matrix (ECM) proteins are being deposited, starting from
the border zone, and progressing into the central area ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transforming growth factor (TGF)-β1, released by a variety
of cells [6], play an important role in the initiation of this
phase. TGF-β1 triggers the differentiation of fibroblasts
into myofibroblasts [7]. These myofibroblasts contribute
to the preservation of the structure and morphology of
the infarcted tissue via their contractile properties and
production of interstitial collagens, which provide tensile
strength in the infarcted myocardium [8]. In addition to
ECM formation, new blood vessels appear in the infarct
three to four days after the ischemic event to supply the
injured area with blood. These vessels are derived from
pre-existing collaterals or are newly formed from endo-
thelial cells that migrate into the wound [9]. Two to
three weeks post-MI (third phase), the infarcted tissue
contains (partly) cross-linked interstitial collagens,
macrophages, blood vessels and (myo)fibroblasts. Follow-
ing this, the fourth and final phase is initiated. Granula-
tion tissue matures into a stabilized scar, cells disappear
from the wound and most of the collagen becomes
cross-linked. Initially, the high ECM content of the scar
preserves the ventricular morphology but, when not
properly maintained, it eventually loses its coherence
resulting in adverse ventricular remodeling [10]. This ad-
verse remodeling involves both the infarcted and non-
infarcted myocardium and causes an increased collagen
deposition in the interstitial space in the remote areas
[11]. There is an increasing body of experimental evi-
dence suggesting that myofibroblasts are responsible for
the maintenance of the ECM in the scar [12].
Many cell types contribute to the process of infarct
healing, having either a beneficial or detrimental role.
Adverse remodeling of the infarct scar will ultimately re-
sult in congestive heart failure (CHF). Current therapies
are only focused on the delay of the progression of CHF.
For this reason, it is important to improve the healing of
the scar in such a way that CHF development can be
prevented. In recent years, more literature has emerged
about Wnt/Frizzled signaling in infarct healing. In this
review we will discuss the involvement of Wnt/Frizzled
signaling in the different phases of infarct healing and
possible therapeutic targets following MI.
Wnt/Frizzled signaling pathway
The Wnt/Frizzled signaling pathway is a transduction cas-
cade of high complexity, which is fundamental for a wide
range of physiological and developmental mechanisms, as
well as disease states [13,14]. The involvement of Wnt sig-
naling in the embryonic myocardial development has re-
cently been described in several reviews [15-17]. A large
number of different Wnt ligands and Frizzled receptors
have been detected in the mesoderm of the heart-forming
fields during embryogenesis, implicating their influence
on different aspects of cardiogenesis. Under normalphysiological conditions the activity of this pathway is sig-
nificantly reduced and may even be silent in some tissues.
However, a general observation in cardiovascular path-
ology is the re-expression of fetal genes [18]. In several
studies, the upregulation of Wnt/Frizzled signaling com-
ponents was observed after MI, implicating their involve-
ment in cardiac repair [19-23]. Recent evidence indicates
upregulated Wnt signaling following MI in progenitor
cells, endothelial cells, leukocytes and fibroblasts through-
out the entire myocardium [19], suggesting a broad role
for Wnt signaling in cardiac repair.
The Wnt/Frizzled signaling pathway comprises of two
major branches, the canonical (involving β-catenin) and
the non-canonical pathways (independent of β-catenin),
which share their main components: Wnts (the ligands)
and Frizzleds (their corresponding receptors). Wnts are
highly conserved glycoproteins (350 to 400 amino acids
long) that are found in many organisms [14]. Nineteen
Wnt members have been identified so far in humans and
are characterized by large cysteine-rich domains [24].
Moreover, the Wnt proteins are extensively palmitoylated,
which makes them highly hydrophobic, hence it is ex-
tremely difficult to purify them [25]. Wnts bind to their
receptors, Frizzleds, which are seven-transmembrane
receptors with sizes varying from 500 to 700 amino acids.
Up to the present time, 10 different Frizzled receptors
have been identified in mammals and all seem to possess
a cysteine-rich domain, which might play a role as a rec-
ognition site for the ligand (Wnt) [13,26]. Furthermore,
the low-density lipoprotein receptor-related protein (LRP)
co-receptors also seem to play an important role in the
Wnt/Frizzled signaling cascade. The major members of
the LRP family are LRP5 and LRP6 and they act as dock-
ing sites for Axin [27].
Endogenous Wnt modulators
Modulation of Wnt signaling can occur through the ac-
tion of several endogenous-secreted proteins. There are
two distinct classes, the soluble frizzled-related protein
(sFRP) class and the Dickkopf (DKK) class, which func-
tion in distinct manners. sFRPs modify Wnt/Frizzled sig-
naling by scavenging Wnt proteins with a frizzled-like
cysteine-rich domain and thereby intervene in the inter-
action between Wnt ligands and Frizzled receptors. The
sFRP family also includes the Wnt inhibitory factor 1
(WIF-1) and Cerberus that function in similar ways.
DKK proteins inhibit Wnt signaling by interacting with
the LRP co-receptors. This causes internalization of the
LRPs and thereby diminishing of the availability of co-
receptors for Wnt signaling [28,29].
The canonical pathway
β-Catenin is the second messenger of the canonical Wnt
signaling pathway and it is the most studied of all. In the
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adenomatous polyposis coli (APC), casein kinase 1 (CK1)
and Axin activate glycogen synthase kinase (GSK) 3β. This
in turn phosphorylates several Ser/Thr residues of β-catenin,
which leads to the ubiquitination of the latter. Hence, β-
catenin is degraded and cannot enter the nucleus in order
to modulate gene transcription (Figure 1A). On the other
hand, upon activation of the Frizzled receptor and the
LRP co-receptor by Wnt, the complex (Wnt-Frizzled-
LRP) directly activates the first downstream protein, Dish-
evelled (Dvl). Dvl directly interacts with Axin and breaks
down the ‘destruction complex’ comprising of APC, Axin,
CK1 and GSK-3β. In this case, β-catenin is no longer
degraded but it accumulates in the cytoplasm and enters
the nucleus where it binds and activates the T-cell factor/
lymphoid enhancer factor (TCF/LEF) proteins. These pro-
teins can bind to DNA and activate the transcription of a
wide range of genes, including c-myc, cyclin D1, c-jun,
fra-1 [30] and many others (Figure 1B). The activation (or
not) of these target genes is of paramount importance,
since they regulate: cell growth and apoptosis (c-myc)Figure 1 Different statuses of the Wnt/Frizzled signaling cascade. (A)
by a Wnt protein. Hence, the β-catenin degradation complex consisting of
residues, which ubiquitinates the latter and leads to degradation of it. As a
target genes. (B) Upon binding of Wnt to the Frizzled receptor and co-loca
destruction complex. Now, β-catenin is accumulating in the cytoplasm and
thereby activates the transcription of a broad range of genes. (C) Wnt prot
of the cysteine-rich binding domains by UM206. In addition, the endogeno
with the Frizzled receptor, thereby blocking the signaling transduction. sFR
Via all these mechanisms, β-catenin is prevented from entering the nucleu[31], cell proliferation, differentiation and response to vari-
ous stimuli (c-jun) [32], cell motility and invasion (fra-1)
[33] and cell cycle (cyclin D1) [34].
The non-canonical pathway
The Wnt/Frizzled transduction cascade is able to signal
via mechanisms that do not involve β-catenin. This can
be accomplished via the Ca2+-dependent pathway, the
Ryk/WIF pathway and the Ror2/c-jun N-terminal kinase
(JNK) pathway. For a more detailed description of these
signaling pathways we refer to some competent reviews
on this subject [35,36].
Myofibroblasts in the infarcted area
The ECM in the heart forms a three-dimensional structure,
which serves as a framework for the attachment of myo-
cytes in order to transmit the mechanical force. The cardiac
fibroblast is the main cell type that is responsible for produ-
cing ECM components. By number, but not by volume, car-
diac fibroblasts are the predominant cell type in the heart
[37]. In the normal adult heart, collagen half-life isWnt/Frizzled signaling is off when the Frizzled receptor is not engaged
GSK-3β, Axin, APC and CK1 phosphorylates β-catenin at Ser/Thr
result, β-catenin cannot enter the nucleus and activate transcription of
lization of the LRP receptor, Dvl is activated, which disrupts the
can enter the nucleus where it activates the TCF/LEF proteins and
eins are prevented from binding to the Frizzled receptor by blockade
us antagonist DKK prevents the LRP co-receptor from co-localization
Ps can scavenge Wnt proteins, which can reduce active Wnt signaling.
s and transcription is not initiated.
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blasts have to be continuously present to replete the
degraded ECM components. Cardiac fibroblasts lack a cell-
specific marker, hence their staining and histological study
is not an easy task [38]. Resting fibroblasts can, under cer-
tain circumstances (for example following MI), become
activated and exhibit contractile properties due to expres-
sion of α-smooth muscle actin (α-SMA) [39]. When a fibro-
blast undergoes this transition, it differentiates into a
myofibroblast. Differentiated fibroblasts also have an
increased secretion of profibrotic molecules such as fibro-
nectin and collagen [40,41]. Myofibroblasts are normally
not present in the healthy adult myocardium but are abun-
dant under pathological conditions, such as a MI where a
fibrotic scar is formed [42]. In addition, dilatation of the in-
farct is counteracted by the presence of myofibroblasts that
produce ECM components and have contractile properties
and thereby can confine the development of CHF [12].
Origin of myofibroblasts in the remodeling heart
Traditionally, it was thought that myofibroblasts were
only derived from resident cardiac fibroblasts. However,
myofibroblasts can also be derived from other precursor
cells [43-49]. There is evidence that myofibroblasts in
the remodeling area of the heart can also originate from
endothelial to mesenchymal transition (endo-MT), epi-
thelial to mesenchymal transition (EMT) and circulating
hematopoietic bone marrow (BM)-derived cells, also re-
ferred to as fibrocytes. Recently, it was shown in mice
that a pool of myofibroblasts in the infarct myocardium
originated from the epicardium seven days post-MI, sug-
gesting an epicardial EMT process [43]. Endo-MT has
been studied in a mouse model of aortic banding, which
resulted in a fibrotic heart. It was reported that fibro-
blasts originating from the endothelium were present in
the fibrotic hearts, whereas they were not observed in
the unbanded hearts. In the same study, the contribution
of BM-derived cells as source of fibroblasts was investi-
gated. It was found that 21.1% of the α-SMA+ cells origi-
nated from BM cells compared to 3.4% in unbanded
hearts [44]. Another study confirms the presence of BM-
derived myofibroblasts in a mouse model of MI. Of all
myofibroblasts present in the infarct area, 24% origi-
nated from BM-cells and were also expressing collagen I
[45], whereas in a similar study 57% of the myofibro-
blasts had a BM origin [46]. More profound research
showed that monocytes could be the precursors of the
hematopoietic BM-derived myofibroblasts in a MI as
well as a pressure overload model [47-49].
Role of Wnt/Frizzled signaling in myofibroblasts following
MI
There is ample evidence suggesting that components of the
Wnt/Frizzled pathway are upregulated in myofibroblastsfollowing MI. Frizzled-2 (Fzd-2) and Dvl-1 have an
increased expression four days after MI and this is located
at the border zone of the infarct. In the course of time, this
expression migrates toward the center of the infarct [22,50].
Previous work from our laboratory suggested that, because
of the expression pattern of α-SMA resembles that of Fzd-
2, myofibroblasts are the cells in which Wnt signaling is
activated [50]. Active canonical Wnt signaling in myofibro-
blasts following MI in mice was observed by Aisagbonhi et
al. [21]. In vitro experiments done by Carthy et al. also
showed canonical signaling upon stimulation with Wnt3a
in mouse fibroblasts [51]. Wnt3a inhibited fibroblast prolif-
eration but increased migration, α-SMA and TGF-β expres-
sion and SMAD2 phosphorylation. Moreover, α-SMA
expression was dependent on β-catenin and TGF-β expres-
sion [51]. In addition, overexpression of β-catenin also
resulted in increased α-SMA expression in cardiac fibro-
blasts [52], which can be expected since cytoplasmic β-
catenin levels are increased when canonical signaling is
active (Figure 1B). Recently, a cell line of immortalized
cardiac fibroblasts was developed in our laboratory. Acti-
vation of Wnt/Frizzled signaling with Wnt3a on Fzd-1
transfected fibroblasts increased α-SMA expression,
whereas stimulation with Wnt5a decreased α-SMA ex-
pression [53]. On the other hand, transfection with Fzd-2
instead of Fzd-1 decreased α-SMA expression upon
stimulation with Wnt3a, whereas Wnt5a increased the ex-
pression. The same pattern was found for other markers
such as collagens and fibronectin [53]. In the same study,
overexpression of β-catenin activated β-catenin-mediated
signaling and induced overexpression of these markers as
well [53]. Additionally, an important finding was the atte-
nuated migration by all tested Wnt/Frizzled combinations
[53], which is in contrast to the findings of Carthy et al.
[51]. On the other hand, proliferation was not affected by
any of the combinations [53]. Research on the effect of
sFRP-2 on proliferation and differentiation of fibroblasts
revealed that sFRP-2 stimulated proliferation but not dif-
ferentiation, since α-SMA expression was not altered [54].
Taken together, these findings support the hypothesis
that differentiation of cardiac fibroblasts and the migrat-
ing properties of the myofibroblast can be modulated by
Wnt/Frizzled signaling. However, it also emphasizes the
complicacy of Wnt/Frizzled signaling in the induction of
myofibroblast differentiation.
Interventions in Wnt/Frizzled signaling following MI
Secreted frizzled-related proteins
Barandon et al. have extensively studied the role of FrzA
(also known as sFRP-1) in cardiac repair [23,55,56]. In
their first study, transgenic (Tg) mice overexpressing
FrzA were subjected to MI. FrzA overexpression had a
profound effect on the healing process following MI
[23]. The incidence of rupture and the size of the infarct
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in FrzA Tg mice. The cellularity in the scar was
improved and was mostly composed of myofibroblasts,
confirmed by α-SMA staining. Moreover, myofibroblasts
and collagen deposition were more concentrically
aligned to the endo- and epicardium in transgenic mice.
Also matrix metalloproteinase (MMP)-2 and −9 activity
was reduced [23], which decreases the chance of cardiac
rupture [57,58]. In addition, early leukocyte infiltration
as well as the apoptotic index was decreased in the first
week after MI [23].
Subsequently, the role of FrzA on angiogenesis fol-
lowing MI was assessed. The capillary density in the
scar was significantly higher in the FrzA Tg mice.
Moreover, the vessel walls were more muscularized and
the mean vessel lumen area was 3-fold higher com-
pared to wild-type controls [55]. Further investigation
into the role of FrzA and the involvement of Wnt/
Frizzled signaling in the post-ischemic inflammatory
process elucidated that FrzA overexpression in leuko-
cytes altered the inflammatory response following MI
[56]. Neutrophil infiltration was significantly reduced
for up to seven days after MI, but there was no differ-
ence in T-lymphocyte or macrophage infiltration. The
pro- and anti-inflammatory cytokine profile changed as
well, since FrzA significantly reduced interleukin-6 and
increased interleukin-10 expression. This correlated
with a reduction in cardiac rupture, scar size and an
overall improvement in cardiac function [56]. Modifica-
tions in inflammatory responses by Wnt signaling have
also been confirmed in other studies that indicate that
Wnt signaling is pro-inflammatory [59-61].
sFRP-2 has also been shown to play a role in myocar-
dial infarct healing [54,62]. In vitro, recombinant sFRP-2
was shown to inhibit the procollagenase activity of bone
morphogenic protein (BMP)-1 in primary cardiac fibro-
blasts, preventing the maturation of type I pro-collagen
[54]. Following MI, newly synthesized type I and type III
collagens were strongly upregulated in the infarct area at
day 3 and expression levels remained high thereafter.
Endogenous sFRP-2 was upregulated in the infarct area
and peaked after three days, followed by a decrement to
undetectable levels after fourteen days. The same pattern
was observed for BMP-1 [54]. Recombinant sFRP-2 in-
jection directly into the heart, two days after MI,
reduced fibrosis by approximately 66%. Even one month
after induction of MI, when the remodeling phase is
normally complete, the amount of fibrosis was still
reduced by approximately 50% [54]. This confirms that
sFRP-2 inhibits collagen maturation in the scar and
thereby has a distinct effect on this process compared to
sFRP-1 [23]. In addition, four weeks after MI, the ratio
of the anterior to posterior wall thickness decreased sig-
nificantly in control animals, whereas this was not thecase in sFRP-2 treated animals. This resulted in an
improved cardiac function four weeks after treatment
since fractional shortening (FS) was increased [54].
In contrast to these data, Kobayashi et al. demon-
strated contradictory results for sFRP-2 [62]. It was
found that sFRP-2 has the ability to enhance the activity
of BMP-1 instead of inhibiting it. This was confirmed in
fibroblast cell cultures of sFRP-2 null mice, where
reduced pro-collagen processing, and deposition of col-
lagen and ECM were observed [62]. Following MI in
mice there was an upregulation of sFRP-2 mRNA ex-
pression at day 4, which peaked at day 7. At day 14 it
was reduced but there was still an increase of 30 to 40-
fold. However, an induced expression on protein level
was not demonstrated. In infarcted sFRP-2 null mice,
Sirius red stained cross-sections showed only 15 to 20%
fibrosis of the left ventricle (LV), compared to 25 to 35%
in wild-type mice. Also cardiac function was preserved
as the ejection fraction (EF) was significantly improved
two weeks post-MI in sFRP-2 null mice [62]. So whereas
He et al. demonstrated that after MI, sFRP-2 injection in
the infarct area improves cardiac function and is able to
inhibit fibrosis and remodeling [54], the latter study by
Kobayashi et al. concluded that the same phenotype
could be observed in sFRP-2 null mice [62]. Even though
the effect of sFRP-2 is completely opposite in the two
studies, Kobayashi et al. monitored the infarct only up
to two weeks [62]. At this time the wound healing is not
completed yet, thus the effect on the complete healing
phase is unknown and needs further investigation.
sFRP-4 has been shown to play a profound role in in-
farct healing as well [63]. In a MI rat model, sFRP-4
mRNA expression in the ischemic area was upregulated.
Following MI, it peaked at three to five days to a 4-fold
increase, and decreased to baseline levels after a month.
Administration of recombinant sFRP-4 in the ischemic
regions increased cardiac function in a dose-dependent
manner. The size of the LV cavity remained normal
whereas this was enlarged in control animals. Also the
acellular scarring was suppressed in sFRP-4 treated
hearts, resulting in a better infarct healing [63].
Collectively, these studies implicate that sFRPs play an
important role in infarct healing and this is probably not
only by the modulating effect between Wnt ligands and
Frizzled receptors but also by other inhibitory or stimu-
lating properties (for example on BMP-1).
Synthetic pharmacological tools
Recently, pyrvinium (an FDA-approved drug) has been
described to possess Wnt signaling inhibiting properties
[64]. It potentiates the downstream molecule CK1,
which is a component of the β-catenin degradation com-
plex. This drug was administered in the peri-infarct area,
directly after infarct induction. After 30 days, LV internal
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compared to control. No other differences in infarct size
or morphology were reported. An increased cell prolif-
eration was observed in the border zone and the remote
area of the pyrvinium-treated hearts, which suggests that
cardiomyocytes re-entered the cell cycle. This was not
due to a better vascularization, since there was no differ-
ence between the groups, but most probably due to in-
hibition of Wnt signaling in cardiomyocytes [64]. A
limitation of this study was that no collagen levels,
MMP expression or other important components for
wound healing were checked.
In our laboratory, we have developed a peptide frag-
ment of Wnt5a (UM206) that occupies the binding sites
for Wnt3a and Wnt5a on the Fzd-1 and −2 receptor,
thereby preventing Wnt signaling (Figure 1C) [65]. This
peptide showed promising results in a mouse model of
MI. Administration of UM206 for five weeks via osmotic
mini pumps completely prevented death due to heart
failure, whereas approximately 30% of the control ani-
mals died after five weeks. Moreover, infarct size was
decreased by UM206 treatment, while neovasculariza-
tion and myofibroblast numbers were increased. Fur-
thermore, total collagen levels in the infarct were
decreased, though collagen Iα1 was upregulated whereas
collagen III was downregulated [65]. Collagen I has a
higher resistance to dilatation of the infarct compared to
collagen III and probably thereby contributes to preser-
vation of cardiac morphology [66]. Hence, treatment
with UM206 improved cardiac function markers and
completely prevented the development of heart failure
[65].
In conclusion, these studies provide evidence that in-
hibition of Wnt/Frizzled signaling can have beneficial
effects on wound healing and can prevent heart failure
after MI.
β-Catenin
β-catenin is a multifunctional protein. It can serve as a
membrane protein that links the cytoplasmic tail of cad-
herin to the actin cytoskeleton by which it maintains the
tissue architecture and cell polarity. On the other hand,
cytoplasmic β-catenin can act as a co-activator to induce
transcription of target genes [67].
Modifications in the expression of β-catenin can also
serve as a tool to inhibit or promote Wnt/Frizzled signal-
ing, since it is a downstream component of the cascade.
In vitro overexpression of β-catenin in cardiomyocytes
and cardiac fibroblasts of rat origin resulted in reduced
apoptosis. It also enhanced vascular endothelial growth
factor (VEGF) expression in both cell types and increased
α-SMA expression in fibroblasts. Besides, it promotes
cell cycle progression but only cell numbers of cardiac
fibroblasts were increased [52]. Based on these results,an in vivo study was performed that had promising
results [52]. In a rat model of MI, overexpression was
achieved by injecting a β-catenin containing adenoviral
vector in the infarct area following induction of MI. One
week after infarction, the amount of apoptotic cells, as
well as the size of the infarcted area, was smaller in the
β-catenin transfected group. Also FS was improved com-
pared to control animals. In concordance with the
in vitro data, there was an increment in VEGF expression
and capillary density [52]. These data suggest that β-
catenin overexpression is able to reduce infarct size and
to improve cardiac function by decreasing apoptosis and
increasing capillary density. However, as with the in vitro
data, no information on α-SMA expression in the
infarcted area was reported, which could give an indica-
tion for a correlation between cardiac function and the
presence of myofibroblasts. Remarkably, another study
showed more favorable results with β-catenin depletion
instead of overexpression [68]. Here, cardiomyocyte-
specific depletion of β-catenin resulted in decreased in-
farct size and mortality as well as improved FS four
weeks after infarction, though there was no difference in
apoptosis. Therefore, apoptosis could not explain the
improved cardiac phenotype. Further research to certify
these effects led to the discovery of enhanced differenti-
ation of cardiac progenitor cells in the infarcted area
[68]. This suggests that resident precursor cells contrib-
ute to the endogenous regeneration of cardiac tissue in
LV remodeling following MI and that this is amplified by
downregulation of β-catenin. The latter two studies inter-
vene at different sites in the myocardium (depletion of β-
catenin in viable cardiomyocytes versus injection in
infarcted area), which may explain the discrepancy. Over-
expression of β-catenin simulates the stimulation of ca-
nonical Wnt/Frizzled signaling, whereas depletion is
associated with inhibition of Wnt/Frizzled signaling,
therefore the latter study is in concordance with previous
studies that showed beneficial results with inhibition of
signaling by means of antagonizing tools.
Neovascularization following MI and the role of Wnt/
Frizzled signaling
Vascularization is important for maintenance of all tis-
sues in the body. The importance of regulated Wnt sig-
naling in vasculogenesis during early developmental
stages has been shown in several studies with disrup-
tions or mutations in the Wnt/Frizzled pathway. Dele-
tion of Wnt-2 or Fzd-5, results in defects of the
placental vasculature in mice [69,70]. Moreover, Wnt-7b
has been shown to be crucial in the development of the
pulmonary vasculature [71]. Furthermore, normal ex-
pression of Fzd-4 and LRP5 is required for vascular
organization during embryogenesis [72]. Vessel forma-
tion and remodeling can also be one of the processes
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following MI. The implication of Wnt/Frizzled signaling
has also been established in such conditions. In an earl-
ier report from our laboratory, it was demonstrated that
cytoplasmic β-catenin and Dvl-1 expression were located
in the endothelial cells of the newly formed and pre-
existing blood vessels of the infarcted area one week
post-MI, whereas this was not observed in the rest of
the heart [73]. More recently, local administration of
DKK-2 in the infarcted heart has been shown to enhance
neovascularization [74]. This implies that impairment of
Wnt/Frizzled signaling ameliorates formation of new
vessels. This concept is strengthened by in vivo MI stud-
ies, which demonstrate increased amount of blood vessels
in the infarcted area when treated with the antagonist
UM206 [65] or overexpression of FrzA [55].
Taken together, the involvement of Wnt/Frizzled sig-
naling in formation of new vessels during pathophysio-
logical conditions is highly evident. Modulation in this
signaling cascade following MI is a potential means of
improving infarct healing.
The role of Wnt/Frizzled signaling in stem cells following
MI
Until the recent discovery of cardiac stem cells (CSCs),
the heart has been viewed as a terminally differentiated
organ. These cardiac progenitor cells are multipotent
and can give rise to new cardiomyocytes, smooth muscle
cells and endothelial cells [75,76]. Hence it was hypothe-
sized that these stem cells could be a potential tool for
the prevention or cure of heart failure following MI. Re-
cently, isolated c-kit+ human CSCs have been shown to
differentiate into myocytes, endothelial cells and smooth
muscle cells in vitro. These differentiated myocytes were
able to contract upon electrical stimulation [77]. Injec-
tion of human CSCs into the infarcted rat/mouse heart
resulted in a chimeric heart that was integrated into the
myocardium of the rodent and contributed positively to
the cardiac performance [77]. Recently, it was shown
that acute MI increased c-kit+ and Sca-1+ cells in the
circulation [78]. These cells were also increased in the
BM one week after MI, indicating an activated BM
niche. In addition, it was demonstrated that canonical
Wnt signaling was activated in mononuclear BM cells of
the mice. Furthermore, Wnt signaling activated human
BM cells and increased their migratory capacity ex vivo
[78], implicating a role for Wnt/Frizzled signaling in
stem cells. Overexpression of β-catenin in ex vivo
expanded hematopoietic progenitor cells (HPCs) has
been shown to decrease infarct size and improve EF, FS
and LV end systolic diameter in mice following injection
of these cells [79], whereas cardiomyocyte specific β-
catenin depletion enhanced cardiac progenitor cell dif-
ferentiation and improved the cardiac phenotype [68].Besides HPCs, mesenchymal stem cells (MSCs) are also
easy to isolate from the BM and can be expanded
ex vivo without losing multipotency [80]. Akt overex-
pression in MSCs augmented the endogenous expression
and release of sFRP-2. The injection of conditioned
medium produced from these cells in infarcted hearts
has been shown to reduce infarct size [81]. Moreover, in-
jection of sFRP-2 overexpressing MSCs in the border
zone of the infarct ameliorated the engraftment and
improved the cardiac phenotype following MI [82].
Wnt signaling is necessary for maintenance of pluripo-
tency [83], whereas the Wnt signaling inhibitor DKK-1
is critical for proliferation [84]. Also, sFRP-2 is respon-
sible for MSC self-renewal by inhibition of the BMP and
Wnt pathway and may improve cardiac wound healing
mediated by MSC engraftment [85]. Furthermore,
Wnt3a decreases the proliferation of CSCs by the activa-
tion of the insulin-like growth factor binding protein 3
through canonical Wnt signaling. In addition, intramyo-
cardial injection of Wnt3a following MI impedes en-
dogenous cardiac regeneration and deteriorates cardiac
function [86]. Taken together, these data show that
modification of Wnt/Frizzled signaling can contribute to
the actions of stem cells during cardiac repair.Conclusion
The wound-healing phase is a critical process for the
clinical outcome of patients who have suffered from MI.
Abnormal remodeling will result in a poorly healed scar
that can cause dilatation of the left ventricle and ultim-
ately progresses into CHF, which can be lethal. Since an
increasing number of patients are affected by this prob-
lem, it is of major importance that therapeutic interven-
tions do not just delay the progression, but rather
prevent the development of CHF. The Wnt/Frizzled
pathway is involved in many aspects of cardiac repair
following MI and may be a promising therapeutic site
for interventions. However, the precise targets and mech-
anism of intervention are still a matter of debate. Thus far,
promising tools have been used in experimental settings,
targeting Wnt/Frizzled signaling at several important sites
involved in infarct healing such as (myo)fibroblasts, pro-
genitor cells, neovascularization, inflammation, collagen
maturation and several others that can contribute to an
improved cardiac phenotype by minimizing the scar and
reducing ventricular dilatation (Figure 2). Wnt/Frizzled
signaling is mostly silent under physiological conditions
but its components can be upregulated in a pathological
state. Because this upregulation is only taking place in the
affected organ, pharmacological tools display a relative se-
lectivity at this site, thereby not affecting other systems or
organs. Therefore, development of strategies that modu-
late Wnt/Frizzled signaling can serve as novel therapeutic
Figure 2 Potential targets of modulations in Wnt signaling to improve cardiac repair. Interventions in Wnt/Frizzled signaling can modulate
several processes such as neovascularization, myofibroblast differentiation and stem cell proliferation/differentiation, which can all contribute to
improved healing of the scar, preservation of cardiac function and thereby prevent development of congestive heart failure (CHF).
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The discussed studies, in which interventions in Wnt
signaling following MI are described (Table 1), have dif-
ferent modes of treatment that may explain the discrep-
ancy in the outcomes. Though, there is a trend that
improved outcomes are more often achieved by inhib-
ition of Wnt signaling. Therefore, in our opinion, block-
ade of Wnt/Frizzled signaling would be the best strategy
to intervene following MI. In addition, many aspects of
the pharmacology and the activation of the differentTable 1 Overview of studies intervening in the Wnt pathway
Study Intervention Effect on Wn
Barandon et al. [23] FrzA overexpression Inhibition
Barandon et al. [56] sFRP-1 overexpression Inhibition
He et al. [54] sFRP-2 administration Inhibition
Kobayashi et al. [62] sFRP-2 deletion ?
Matsushima et al. [63] sFRP-4 i.m. administration Inhibition
Saraswati et al. [64] Pyrvinium administration Inhibition
Laeremans et al. [65] UM206 administration Inhibition
Hahn et al. [52] β-catenin Stimulation
overexpression
Zelarayan et al. [68] Cardiomyocyte specific
- β-catenin depletion - Inhibition
- β-catenin stabilization - Stimulation
LVIDD, left ventricular internal diameter in diastole; MI, myocardial infarction; sFRP,signal transduction pathways by different combinations
of Wnts and Fzds are far from completely understood.
Therefore, more research is needed in testing different
Wnt/Fzd combinations and the subsequent activation of
the signaling pathway. Besides, further investigations are
necessary to compare interventions in different types of
MI (permanent ligation versus ischemia and reperfusion)
and different animal models.
Abbreviations
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